EVP & CAO of $CCK sells 8,222 shares in insider sale
Congress have participated in trading $CCK stock once in the previous 6 months, with 0 purchases and 1 sale occurring during this period. The single transaction involved Representative Thomas H. Kean, Jr., who sold up to $15,000 of $CCK stock on May 8th. For more details on congressional stock trading activities, Quiver Quantitative offers a congressional trading dashboard for tracking purposes.
Analysts on Wall Street have analyzed $CCK in recent months, resulting in 7 firms issuing buy recommendations for the stock, with no sell recommendations. These reports reflect positive sentiment towards the company, with firms such as Mizuho, UBS, and B of A Securities offering ratings ranging from “Outperform” to “Buy” and “Overweight.” It is essential to monitor such analyst ratings and price targets for $CCK by utilizing Quiver Quantitative’s $CCK forecast page.
Moreover, multiple analysts have established price targets for $CCK in the past few months, with a median target of $118.0 among the 13 analysts who provided predictions. Notable analysts like Jeffrey Zekauskas from JP Morgan and Michael Roxland from Truist Securities have set target prices for the stock, ranging from $110.0 to $140.0. These price targets serve as valuable indicators for investors seeking to make informed decisions regarding $CCK stock.
In conclusion, insider trading activities, hedge fund movements, congressional stock trades, analyst ratings, and price targets all contribute to the comprehensive analysis of $CCK stock performance and market outlook. Monitoring these factors through Quiver Quantitative’s specialized dashboards can offer valuable insights to investors and market participants. It is essential to conduct thorough research and analysis before making any investment decisions related to $CCK and other stocks. This article is intended for informational purposes only and does not constitute financial advice. For additional information, refer to Quiver Quantitative’s disclaimers.